All In Biotech

Drug Trial Radar · NCT06721494

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

Feb 5, 2026

Primary completion

Oct 24, 2026

Study completion Oct 29, 2026

Sponsor

Lead sponsor
Clear Scientific, Inc.Industry
Sponsor type
Industry
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Dec 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

Conditions

  • Methamphetamine Intoxication
  • Methamphetamine Disorders
  • Methamphetamine Abuse

Interventions

  • MethamphetamineDrug

    Methamphetamine HCl for intravenous administration

  • Sterile SalineDrug

    Sterile Saline for intravenous administration

  • CS-1103Drug

    CS-1103 for intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with CS-1103-related adverse events (AEs) assessed by physical examinationsTime frame: 3 days plus follow-up on Day 10
  2. Number of participants with CS-1103-related adverse events (AEs) assessed by electrocardiograms (ECGs)Time frame: 3 days plus follow-up on Day 10
  3. Number of participants with CS-1103-related adverse events (AEs) assessed by vital signsTime frame: 3 days plus follow-up on Day 10
  4. Number of participants with CS-1103-related adverse events (AEs) assessed by laboratory parametersTime frame: 3 days plus follow-up on Day 10
  5. Time course and magnitude of urine excretion of methamphetamineTime frame: 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • California Clinical Trials Medical Group

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.